TG Therapeutics (TGTX) free cash flow

Free cash flow · fiscal 2025
-$24.99M

TG Therapeutics (TGTX) generated free cash flow of -$24.99M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$40.56M. Figures as of 18 Nov 2026, 12:25 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
-$24.99M
Highest on record
-$86.58Kfiscal 2011
Lowest on record
-$296.04Mfiscal 2021
Fiscal years on record
152011–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

TG Therapeutics free cash flow, in more detail

Across the 15 fiscal years on record (2011–2025), the highest was -$86.58K in fiscal 2011 and the lowest -$296.04M in fiscal 2021.

History · 15 fiscal years

Free cash flow by fiscal year

TG Therapeutics free cash flow, year by year

TG Therapeutics (TGTX) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025-$24.99M—
2024-$40.56M—
2023-$31.41M—
2022-$176.18M—
2021-$296.04M—
2020-$214.86M—
2019-$132.94M—
2018-$129.02M—
2017-$93.76M—
2016-$61.93M—
2015-$44.73M—
2014-$35.08M—
2013-$10.74M—
2012-$5.19M—
2011-$86.58K—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of TG Therapeutics and comparable companies
CompanyFree cash flowFiscal year
Madrigal Pharmaceuticals MDGL-$193.02M2025
Henry Schein HSIC$521.00M2025
Oscar Health OSCR$1.06B2025
TG Therapeutics TGTX-$24.99M2025
Praxis Precision Medicines PRAX-$249.12M2025
Twist Bioscience TWST-$95.96M2026

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on TGTX

TG Therapeutics, figure by figure

TG Therapeutics (TGTX) overview: price, valuation and scorecardAll health care companies by market value

TG Therapeutics free cash flow: questions and answers

What is TG Therapeutics's free cash flow?

TG Therapeutics (TGTX) generated free cash flow of -$24.99M in fiscal 2025 (the year ended December 31, 2025). In fiscal 2024 the figure was -$40.56M.

What are the highest and lowest free cash flow figures on record for TG Therapeutics?

Across the 15 fiscal years on record (2011–2025), the highest was -$86.58K in fiscal 2011 and the lowest -$296.04M in fiscal 2021.

How is TG Therapeutics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For TG Therapeutics it is on record here for 15 fiscal years, 2011 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “TG Therapeutics (TGTX) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/TGTX/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.